|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/09/22 Celldex Therapeutics, Inc. 10-Q 9/30/22 62:6.5M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.36M
2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 155K
3: EX-10.1 Material Contract HTML 282K
4: EX-10.2 Material Contract HTML 41K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 24K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 20K
13: R1 Document and Entity Information HTML 73K
14: R2 Condensed Consolidated Balance Sheets HTML 111K
15: R3 Condensed Consolidated Balance Sheets HTML 35K
(Parenthetical)
16: R4 Condensed Consolidated Statements of Operations HTML 93K
and Comprehensive Loss
17: R5 Condensed Consolidated Statements of Cash Flow HTML 88K
18: R6 Basis of Presentation HTML 25K
19: R7 Significant Accounting Policies HTML 22K
20: R8 Fair Value Measurements HTML 97K
21: R9 Marketable Securities HTML 111K
22: R10 Intangible Assets HTML 20K
23: R11 Other Long-Term Liabilities HTML 37K
24: R12 Stockholders' Equity HTML 199K
25: R13 Stock-Based Compensation HTML 82K
26: R14 Accumulated Other Comprehensive Income HTML 41K
27: R15 Revenue HTML 24K
28: R16 Income Taxes HTML 23K
29: R17 Net Loss Per Share HTML 28K
30: R18 Kolltan Acquisition HTML 28K
31: R19 Significant Accounting Policies (Policies) HTML 20K
32: R20 Fair Value Measurements (Tables) HTML 95K
33: R21 Marketable Securities (Tables) HTML 109K
34: R22 Other Long-Term Liabilities (Tables) HTML 35K
35: R23 Stockholders' Equity (Tables) HTML 193K
36: R24 Stock-Based Compensation (Tables) HTML 84K
37: R25 Accumulated Other Comprehensive Income (Tables) HTML 39K
38: R26 Net Loss Per Share (Tables) HTML 26K
39: R27 Basis of Presentation (Details) HTML 31K
40: R28 Fair Value Measurements (Details) HTML 43K
41: R29 Fair Value Measurements - Contingent Consideration HTML 26K
Liabilities (Details)
42: R30 Fair Value Measurements - Additional information HTML 29K
(Details)
43: R31 Marketable Securities (Details) HTML 60K
44: R32 Marketable Securities - Additional Information HTML 22K
(Details)
45: R33 Intangible Assets (Details) HTML 22K
46: R34 Other Long-Term Liabilities (Details) HTML 32K
47: R35 Other Long-Term Liabilities- New Jersey tax HTML 26K
benefits (Details)
48: R36 Stockholders' Equity (Details) HTML 71K
49: R37 Stock-Based Compensation - Stock Option Activity HTML 64K
(Details)
50: R38 Stock-Based Compensation - Employee Stock Option HTML 30K
and Incentive Plan Activity Additional Information
(Details)
51: R39 Stock-Based Compensation - Expenses (Details) HTML 25K
52: R40 Stock-Based Compensation - Valuation (Details) HTML 36K
53: R41 Accumulated Other Comprehensive Income (Details) HTML 38K
54: R42 Revenue (Details) HTML 35K
55: R43 Income Taxes (Details) HTML 19K
56: R44 Net Loss Per Share (Details) HTML 22K
57: R45 Kolltan Acquisition (Details) HTML 36K
60: XML IDEA XML File -- Filing Summary XML 105K
58: XML XBRL Instance -- cldx-20220930x10q_htm XML 1.60M
59: EXCEL IDEA Workbook of Financial Reports XLSX 84K
9: EX-101.CAL XBRL Calculations -- cldx-20220930_cal XML 118K
10: EX-101.DEF XBRL Definitions -- cldx-20220930_def XML 332K
11: EX-101.LAB XBRL Labels -- cldx-20220930_lab XML 771K
12: EX-101.PRE XBRL Presentations -- cldx-20220930_pre XML 538K
8: EX-101.SCH XBRL Schema -- cldx-20220930 XSD 95K
61: JSON XBRL Instance as JSON Data -- MetaLinks 252± 394K
62: ZIP XBRL Zipped Folder -- 0001104659-22-116466-xbrl Zip 320K
Exhibit 31.2
CERTIFICATION
I, Sam Martin, certify that:
1. | I have reviewed this report on Form 10-Q of Celldex Therapeutics, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| | |
Date: November 9, 2022 | By: | /s/ SAM MARTIN |
| Name: | |
| Title: | Senior Vice President and Chief Financial Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/9/22 | 8-K | ||
| For Period end: | 9/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/26/24 Celldex Therapeutics, Inc. 10-K 12/31/23 87:8.5M Toppan Merrill/FA2 11/03/23 Celldex Therapeutics, Inc. S-3ASR 11/03/23 4:275K Toppan Merrill/FA 2/28/23 Celldex Therapeutics, Inc. 10-K 12/31/22 85:8.1M Toppan Merrill/FA |